2500 Crosspark Road
Immortagen, founded by the nation’s leading researchers in women’s cancer, seeks to personalize cancer treatment through private tumor banking, full spectrum genetic profiling, revolutionary Clinical Decision Support algorithms, and advanced mouse models for drug research and development. While great strides have been made in the treatment of cancer, cancer treatment today is still a one-size-fits-all approach. From the latest research, it is well-known that every individual tumor has a unique genetic profile that makes it responsive to one treatment over the other. Yet chemotherapeutic agents, which are standard treatment, do not distinguish which mutations are driving the tumor’s growth.
President & CEO: Kurt Heiar
Co-Founder & CSO: Don Dai, MD, PhD, MS
Co-Founder & VP for Business Development: Kristi Thiel, PhD
Co-Founder & Director of Product Development: Baoli Yang, MD, PhD
Director of Operations: Dan Cummins, MBA
Please click here for Immortagen job opportunities.